Serum adropin as a predictive biomarker of erectile dysfunction in coronary artery disease patients

Basit Öğe Kaydı
dc.authoridYILDIRIM, MEHMET/0000-0003-4768-4537
dc.contributor.authorCelik, Husetin Tugrul
dc.contributor.authorBilen, Mehmet
dc.contributor.authorKazanci, Fatmanur
dc.contributor.authorYildirim, Mehmet Erol
dc.contributor.authorIncebay, Ilkay Bekir
dc.contributor.authorErdamar, Husamettin
dc.date.accessioned2025-10-24T18:10:08Z
dc.date.available2025-10-24T18:10:08Z
dc.date.issued2019
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractIntroduction Erectile dysfunction (ED) is associated with various comorbidities and an early diagnosis and treatment is necessary to avoid the development of these comorbidities. Unfortunately, there is no biochemical marker that can be used for early diagnosis of ED. Nitric oxide (NO) is released by nerve and endothelial cells in the corpora cavernosa of the penis and is believed to be the main vasoactive chemical mediator of penile erection. Adropin is a regulatory peptide which has effects on NO bioavailability and energy homeostasis. We hypothesized that adropin may contribute to the pathogenesis of ED because of the presence of both metabolic effects and the influence on NO bioavailability. To confirm this hypothesis, we investigated the relationship between ED and serum adropin and NO levels. Materials and Methods: Seventy-five ED patients were enrolled for this study and the patients were divided into two groups according to angiographic scoring. Serum NO and adropin levels were measured by the Griess reaction and ELISA method, respectively. Results: Serum adropin and NO levels were found to be lower in the group which has higher angiographic score and the difference in NO was statistically significant. Also, adropin has a significant correlation between IIEF scores in ED patients. Conclusion: This is the first study in the literature investigating the levels of adropin in ED patients having coronary artery disease. The adropin molecule shows a promising future in clarifying the etiopathogenesis of ED. More comprehensive and multicenter studies are needed to reveal the role of adropin in ED and the effects of treatment on this molecule.
dc.identifier.doi10.5173/ceju.2019.1666
dc.identifier.endpage306
dc.identifier.issn2080-4806
dc.identifier.issn2080-4873
dc.identifier.issue3
dc.identifier.pmid31720034
dc.identifier.scopus2-s2.0-85073408094
dc.identifier.scopusqualityQ3
dc.identifier.startpage302
dc.identifier.urihttps://doi.org/10.5173/ceju.2019.1666
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3995
dc.identifier.volume72
dc.identifier.wosWOS:000505929200012
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPolish Urological Assoc
dc.relation.ispartofCentral European Journal Of Urology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectadropin; ELISA; erectile dysfunction; nitric oxide
dc.titleSerum adropin as a predictive biomarker of erectile dysfunction in coronary artery disease patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu